Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Immune checkpoint inhibitors ( ICI s) continue to revolutionize current oncology ; Driven by Decision Resources Group’s in-house oncology experts and robust real-world data capabilities, the Real World Brand Tracker captures claims data to uncover shifting market dynamics and the impact of events on the ICI space, in order to help refine your oncology brand strategies. We cover every approved immune checkpoint inhibitor for every approved oncology indication and monitor the trends in use and reimbursement dynamics over time.
How is the uptake for individual ICIs brands changing over time?
Which brand is winning, and how does that vary by indication?
How does the dynamic regulatory environment for ICIs in the US affect prescribing patterns of currently approved ICIs by indication?
What is the average claim charge for each ICI brand and how much if the claim is paid?
In which type of facilities are patients receiving ICIs?